S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:BLGO

BioLargo Stock Forecast, Price & News

$0.23
0.00 (0.00%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.23
$0.23
50-Day Range
$0.17
$0.23
52-Week Range
$0.12
$0.35
Volume
228,889 shs
Average Volume
502,922 shs
Market Capitalization
$58.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive BLGO News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLargo and its competitors with MarketBeat's FREE daily newsletter.


BioLargo logo

About BioLargo

BioLargo, Inc. engages in the provision of technology solutions for odor and moisture control, disinfection, and water treatment. It operates through the following segments: Odor-No-More, BLEST, BioLargo Water, Clyra Medical and Corporate Operations. The Odor-No-More segment manufactures and sells odor and VOC control products and services, including its flagship product, CupriDyne Clean. The BLEST segment offers professional engineering services through its internal business units. The BioLargo Water is a Canadian division which focuses on commercializing AOS systems. The Clyra Medical segment focuses on the advanced wound care industry. The corporate operations segment supports the operating segments with legal, accounting, human resources, and other related services. The company was founded in 1989 and is headquartered in Westminster, CA.

Headlines

BioLargo (NASDAQ:BLGO) Trading Down 1.9%
December 4, 2021 |  americanbankingnews.com
BioLargo (NASDAQ:BLGO) Trading Down 1.3%
November 12, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:BLGO
Fax
N/A
Employees
27
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$58.25 million
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.80 out of 5 stars

Basic Materials Sector

216th out of 222 stocks

Chemicals Industry

1st out of 1 stocks

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












BioLargo (NASDAQ:BLGO) Frequently Asked Questions

How has BioLargo's stock price been impacted by COVID-19 (Coronavirus)?

BioLargo's stock was trading at $0.1910 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BLGO stock has increased by 19.0% and is now trading at $0.2272.
View which stocks have been most impacted by COVID-19
.

Who are BioLargo's key executives?

BioLargo's management team includes the following people:
  • Dennis P. Calvert, Chairman, President & Chief Executive Officer
  • Joseph L. Provenzano, Secretary, Director & Executive VP-Operations
  • Charles K. Dargan, Chief Financial Officer
  • Kenneth Reay Code, Director & Chief Science Officer
  • A. J. Sexton, Director-Business Development

What other stocks do shareholders of BioLargo own?

What is BioLargo's stock symbol?

BioLargo trades on the NASDAQ under the ticker symbol "BLGO."

How do I buy shares of BioLargo?

Shares of BLGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLargo's stock price today?

One share of BLGO stock can currently be purchased for approximately $0.23.

How much money does BioLargo make?

BioLargo has a market capitalization of $58.25 million.

How many employees does BioLargo have?

BioLargo employs 27 workers across the globe.

What is BioLargo's official website?

The official website for BioLargo is www.biolargo.com.

Where are BioLargo's headquarters?

How can I contact BioLargo?

BioLargo's mailing address is 14921 Chestnut St, Westminster, California 92683-5215. The company can be reached via phone at (949) 643-9540.


This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.